Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer

References

• Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, Wang X, Zou J, Han X, Feng D. Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst Rev 2010; Sep 8;(9):CD007414; PMID:20824860; http://dx.doi.org/10.1002/14651858.CD007414.pub2
   PubMed Web of Science ®Google Scholar
• Lavoue V, Thedrez A, Leveque J, Foucher F, Henno S, Jauffret V, Belaud-Rotureau MA, Catros V, Cabillic F. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med 2013; 11:147; PMID:23763830; http://dx.doi.org/10.1186/1479-5876-11-147
   PubMed Web of Science ®Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49:1374-403; PMID:23485231; http://dx.doi.org/10.1016/j.ejca.2012.12.027
   PubMed Web of Science ®Google Scholar
• Kumar J, Ward AC. Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications. Biochim Biophys Acta 2014; 1845:117-25; PMID:24388871
   PubMed Web of Science ®Google Scholar
• Tan DS, Kaye S. Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol 2007; 60:355-60; PMID:17018684; http://dx.doi.org/10.1136/jcp.2006.040030
   PubMed Web of Science ®Google Scholar
• Tomsova M, Melichar B, Sedlakova I, Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008; 108:415-20; PMID:18037158; http://dx.doi.org/10.1016/j.ygyno.2007.10.016
   PubMed Web of Science ®Google Scholar
• Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005; 11:8326-31; PMID:16322292; http://dx.doi.org/10.1158/1078-0432.CCR-05-1244
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-49; PMID:15322536; http://dx.doi.org/10.1038/nm1093
   PubMed Web of Science ®Google Scholar
• Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009; 58:449-59; PMID:18791714; http://dx.doi.org/10.1007/s00262-008-0583-5
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177
   PubMed Web of Science ®Google Scholar
• Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T, Lu J, Liu J. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat 2013; 12:259-67; PMID:23289476
   PubMed Web of Science ®Google Scholar
• Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, Wei YQ. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 2012; 7:e50946; PMID:23284651; http://dx.doi.org/10.1371/journal.pone.0050946
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
   PubMed Web of Science ®Google Scholar
• Dijkgraaf EM, Welters MJ, Nortier JW, van der Burg SH, Kroep JR. Interleukin-6interleukin-6 receptor pathway as a new therapy target in ovarian cancer. Curr Pharm Des 2012; 18(25):3816-27; PMID:22591418
   PubMed Web of Science ®Google Scholar
• Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9:4653-65; PMID:14581334
   PubMed Web of Science ®Google Scholar
• Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X, Xu RC. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 2012; 59:228-36; PMID:22595649; http://dx.doi.org/10.1016/j.cyto.2012.04.020
   PubMed Web of Science ®Google Scholar
• Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J et al. Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. Clin Cancer Res 2011; 17:6083-96; PMID:21795409; http://dx.doi.org/10.1158/1078-0432.CCR-11-0945
   PubMed Web of Science ®Google Scholar
• Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans R, Jha V, Nortier JW, Welters MJ, Kroep JR, van der Burg SH. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res 2013; 73:2480-2492; PMID:23436796; http://dx.doi.org/10.1158/0008-5472.CAN-12-3542
   PubMed Web of Science ®Google Scholar
• Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet 1999; 64:5-10; PMID:10190664; http://dx.doi.org/10.1016/S0020-7292(98)00234-3
   PubMedGoogle Scholar
• Scully RE. World Health Organization classification and nomenclature of ovarian cancer. Natl Cancer Inst Monogr 1975; 42:5-7; PMID:1234636
   PubMedGoogle Scholar
• Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 2004; 17:790-797; PMID:15073602; http://dx.doi.org/10.1038/modpathol.3800120
   PubMed Web of Science ®Google Scholar
• Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-47; PMID:9662379; http://dx.doi.org/10.1038/nm0798-844
   PubMed Web of Science ®Google Scholar
• Ruiter DJ, Ferrier CM, van Muijen GN, Henzen-Logmans SC, Kennedy S, Kramer MD, Nielsen BS, Schmitt M. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer 1998; 34:1334-40; PMID:9849413; http://dx.doi.org/10.1016/S0959-8049(98)00151-8
   PubMed Web of Science ®Google Scholar
• de Vos van Steenwijk PJ, Ramwadhdoebe TH, Goedemans R, Doorduijn EM, van Ham JJ, Gorter A, van HT, Kuijjer ML, van Poelgeest MI, van der Burg SH et al. Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma. Int J Cancer 2013; 133:2884-94; PMID:23740735
   PubMed Web of Science ®Google Scholar
• Kuijjer ML, Namlos HM, Hauben EI, Machado I, Kresse SH, Serra M, Llombart-Bosch A, Hogendoorn PC, Meza-Zepeda LA, Myklebost O et al. mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts. BMC Med Genomics 2011; 4:66; PMID:21933437; http://dx.doi.org/10.1186/1755-8794-4-66
   PubMed Web of Science ®Google Scholar
• Figel AM, Brech D, Prinz PU, Lettenmeyer UK, Eckl J, Turqueti-Neves A, Mysliwietz J, Anz D, Rieth N, Muenchmeier N et al. Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations. Am J Pathol 2011; 179:436-51; PMID:21703422; http://dx.doi.org/10.1016/j.ajpath.2011.03.011
   PubMed Web of Science ®Google Scholar
• Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 1983; 62:124-32; PMID:6190518
   PubMed Web of Science ®Google Scholar
• Van GH, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol 2010; 47:1650-1660; PMID:20299103; http://dx.doi.org/10.1016/j.molimm.2010.02.008
   PubMed Web of Science ®Google Scholar
• Figel AM, Brech D, Prinz PU, Lettenmeyer UK, Eckl J, Turqueti-Neves A, Mysliwietz J, Anz D, Rieth N, Muenchmeier N et al. Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations. Am J Pathol 2011; 179:436-51; PMID:21703422; http://dx.doi.org/10.1016/j.ajpath.2011.03.011
   PubMed Web of Science ®Google Scholar
• Maniecki MB, Moller HJ, Moestrup SK, Moller BK. CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. Immunobiology 2006; 211:407-17; PMID:16920480; http://dx.doi.org/10.1016/j.imbio.2006.05.019
   PubMed Web of Science ®Google Scholar
• Maniecki MB, Moller HJ, Moestrup SK, Moller BK. CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. Immunobiology 2006; 211:407-17; PMID:16920480; http://dx.doi.org/10.1016/j.imbio.2006.05.019
   PubMed Web of Science ®Google Scholar
• Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 2009; 59:300-305; PMID:19432671; http://dx.doi.org/10.1111/j.1440-1827.2009.02369.x
   PubMed Web of Science ®Google Scholar
• Diao J, Mikhailova A, Tang M, Gu H, Zhao J, Cattral MS. Immunostimulatory conventional dendritic cells evolve into regulatory macrophage-like cells. Blood 2012; 119:4919-27; PMID:22490680; http://dx.doi.org/10.1182/blood-2011-11-392894
   PubMed Web of Science ®Google Scholar
• Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M, Meng G, Benjamin WH, Orenstein JM, Smith PD. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 2005; 115:66-75; PMID:15630445; http://dx.doi.org/10.1172/JCI200519229
   PubMed Web of Science ®Google Scholar
• Rath KS, Funk HM, Bowling MC, Richards WE, Drew AF. Expression of soluble interleukin-6 receptor in malignant ovarian tissue. Am J Obstet Gynecol 2010; 203:230-238; PMID:20471626; http://dx.doi.org/10.1016/j.ajog.2010.03.034
   PubMed Web of Science ®Google Scholar
• Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, Li LZ. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010; 295:110-123; PMID:20236757; http://dx.doi.org/10.1016/j.canlet.2010.02.019
   PubMed Web of Science ®Google Scholar
• Cohen S, Bruchim I, Graiver D, Evron Z, Oron-Karni V, Pasmanik-Chor M, Eitan R, Bernheim J, Levavi H, Fishman A et al. Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2. J Mol Med (Berl) 2013; 91:357-68; PMID:23052480
   PubMed Web of Science ®Google Scholar
• Coward JI, Kulbe H. The role of interleukin-6 in gynaecological malignancies. Cytokine Growth Factor Rev 2012; 23:333-42; PMID:23031497; http://dx.doi.org/10.1016/j.cytogfr.2012.08.005
   PubMed Web of Science ®Google Scholar
• Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38:904-10; PMID:22651903; http://dx.doi.org/10.1016/j.ctrv.2012.04.007
   PubMed Web of Science ®Google Scholar
• Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994; 73:1882-88; PMID:8137215; http://dx.doi.org/10.1002/1097-0142(19940401)73:7<1882::AID-CNCR2820730718>3.0.CO;2-R
   PubMed Web of Science ®Google Scholar
• Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, Krause M, Schworer AM, Wagner U, Muller-Brusselbach S et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer 2014; 134:32-42; PMID:23784932; http://dx.doi.org/10.1002/ijc.28335
   PubMed Web of Science ®Google Scholar
• Ko SY, Ladanyi A, Lengyel E, Naora H. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol 2014; 184:271-81; PMID:24332016; http://dx.doi.org/10.1016/j.ajpath.2013.09.017
   PubMed Web of Science ®Google Scholar
• Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL. The Ratios of CD8(+) T Cells to CD4(+)CD25(+) FOXP3(+) and FOXP3(-) T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer. PLoS One 2013; 8:e80063; PMID:24244610; http://dx.doi.org/10.1371/journal.pone.0080063
   PubMed Web of Science ®Google Scholar